The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.
French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham.
The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan. 15, ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
The FDA says that food companies will have until Jan. 15, 2027 to stop using the dye. Drugmakers will have an extra year, until January 2028, to comply with the change. Red 3, also known as ...
Red Dye No. 3, or erythrosine, is a synthetic red food dye once popular in candies and cakes. The ... [+] FDA bans Red Dye No. 3 under the Delaney Clause, citing cancer risks observed in lab ...
On Wednesday, the Food and Drug Administration (FDA) proscribed the dye based on a 2022 petition by consumer advocacy groups against its use, which had already been banned in cosmetics 35 years ago.
"FDA is revoking the authorized uses in food and ingested drugs of FD&C Red No 3 in the color additive regulations," said a document from the Department of Health and Human Services, published in the ...
Officials cited a statute known as the Delaney Clause, which requires FDA to ban any additive found to cause cancer in people or animals. The dye is known as erythrosine, FD&C Red No. 3 or Red 3.
New FDA Consultant is the former Director of the Division of Imaging ... C.R Bard, Smiths Medical, ACMI, Genzyme, Pfizer Hospital Products, and various start-ups. He is the former VP of Regulatory ...
FDA's new "nutrition info box" focuses on telling people whether levels of saturated fat, sodium and added sugar are "high" or "medium" or "low" as well as the percentage for each serving.
The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that ...